In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin.
Aim of this investigation was to study the in vivo and in vitro drug interaction of glimepride with atorvastatin and rosuvastatin. In vitro drug interaction of glimepride with atorvastatin and rosuvastatin was studied using human pooled liver microsomes and evaluated using high performance liquid chromatography. In vivo pharmacokinetic drug interaction of glimepride (6 mg/kg) in coadministration with atorvastatin (60 mg/kg) and rosuvastatin (60 mg/kg) were studied in rats and analyzed using liquid chromatography tandem mass spectrometry (LC-MS/MS). In in vitro study, atorvastatin decreased its own metabolism as well as the metabolism of glimepiride. Rosuvastatin coadministration with glimepride reduced the metabolism of glimepride and increased the metabolism of its own. In in vivo study, concentration in plasma, C(max), AUC((0-t)) and AUC((0-∞)) (area under the concentration-time curve, AUC) of glimepride was increased significantly in coadministration with atorvastatin whereas there was no significant change was observed in the case of coadministration with rosuvastatin. Half life (T(1/2)) and volume of distribution (V(d)) of glimepride decreased significantly with both atorvastatin and rosuvastatin. Elimination rate constant, K(el) of glimepride increased significantly with both atorvastatin and rosuvastatin. Clearance (Cl) of glimepride decreased significantly but the decrease was more with atorvastatin than with rosuvastatin. It is concluded that glimepride metabolism is little affected by rosuvastatin in vitro, which agreed with the negligible interaction in in vivo study. Thus, from safety point of view rosuvastatin is better to prescribe as a coadministration therapy with glimepiride. On the other hand, atorvastatin could cause an increase in the bioavailability of glimepride per oral and also significantly decrease the metabolism of glimerpride in in vitro study. This may pose a positive implication in clinical practice.
Department of Pharmacology, A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, Vallabh Vidyanagar - 388120, Gujarat, India.
Vj
V
Galani
M
M
Vyas
Drugs. 1999;58 Suppl 1:47-51; discussion 75-82
10576525
AAPS J. 2009 Jun;11(2):300-6
19418230
J Clin Pharmacol. 1995 Oct;35(10):957-66
8568013
Int J Diabetes Dev Ctries. 2009 Apr;29(2):74-9
20142872
Ann Intern Med. 2004 Apr 20;140(8):644-9
15096336
Am J Health Syst Pharm. 1998 Nov 1;55(21):2253-67; quiz 2302-3
9825877
Diabetes Care. 2006 Jul;29(7):1478-85
16801565
Curr Drug Metab. 2000 Dec;1(4):305-31
11465042
Eur J Clin Pharmacol. 2001 Aug;57(5):357-64
11599653
J Diabetes Complications. 2000 Jul-Aug;14(4):201-6
11004429
J Clin Pharmacol. 2002 Sep;42(9):963-70
12211221
Ann Intern Med. 2004 Apr 20;140(8):650-8
15096337
Drugs. 1998 Apr;55(4):563-84
9561345